Loading
institutionsInstitution
Harold C. Simmons Comprehensive Cancer Center, UT Southwestern
North Texas's NCI comprehensive centre, where the HIF-2 inhibitor belzutifan, stereotactic body radiotherapy and the cGAS-STING pathway were born.
Also called: Simmons Cancer Center
Overview
NCI-designated in 2010 and comprehensive since 2015, Simmons is the only NCI comprehensive centre in North Texas and is directed by breast oncologist Carlos Arteaga. James Brugarolas's kidney cancer programme and the UTSW spin-out Peloton Therapeutics produced the HIF-2 alpha inhibitor belzutifan, acquired by Merck in 2019 and approved for VHL disease and renal cell carcinoma. Robert Timmerman pioneered stereotactic body radiotherapy for lung and other tumours, and Zhijian 'James' Chen discovered the cGAS-STING innate immune sensing pathway that STING agonists exploit. Ralph DeBerardinis's cancer metabolism work at Children's Medical Center Research Institute adds a strong basic science programme.
Location
Dallas, TX, US
Type
cancer center · UT Southwestern Medical Center
Newsweek 2026 oncology rank
Not in top 300 listing used
NCI designation
comprehensive
OnCo score
#90 · 41 points (0 Newsweek + 15 NCI + 26 from 13 linked objects) · ranking
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-09-17.
Matched to The University of Texas Southwestern Medical Center, including child institutions. 1,744 works · 19,757 citations · 66% open access · 10% clinical trials · 2% reviews.
Oncology works per year
3662022
3682023
3702024
3922025
2482026
Most works
- Patricio M. Polanco69 works
- Herbert J. Zeh56 works
- Larry D. Anderson53 works
- Farrukh T. Awan47 works
- David E. Gerber44 works
- Heather L. McArthur43 works
- Aimaz Afrough43 works
- Matthew R. Porembka40 works
- Amit G. Singal39 works
- Adam C. Yopp38 works
Most cited
- Kidney cancer and HIF-2
- Stereotactic body radiotherapy
- Innate immunity (cGAS-STING)
- Cancer metabolism
Similar pages
- TrialLITESPARK-022
Shares HIF-2α, Belzutifan, Merck & Co. (MSD), Renal cell carcinoma.
- TrialLITESPARK-005
Shares HIF-2α, Belzutifan, Merck & Co. (MSD), Renal cell carcinoma.
- TrialA Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013)
Shares Belzutifan, Merck & Co. (MSD), Renal cell carcinoma.
- PersonWilliam G. Kaelin Jr.
Shares HIF-2α, Belzutifan, Renal cell carcinoma.
- TrialSubstudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (
Shares Belzutifan, Merck & Co. (MSD), Renal cell carcinoma.
- TrialLITESPARK-012
Shares Belzutifan, Merck & Co. (MSD), Renal cell carcinoma.
- TrialA Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6
Shares Belzutifan, Merck & Co. (MSD), Renal cell carcinoma.
- TermVon Hippel-Lindau disease
Shares HIF-2α, Belzutifan, Renal cell carcinoma.
cancers
fronts
technologies
targets
drugs
ApprovedSmall-molecule HIF-2α inhibitor
Belzutifan · Welireg